[Federal Register Volume 75, Number 243 (Monday, December 20, 2010)]
[Notices]
[Pages 79407-79412]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2010-31853]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-350E]
Established Assessment of Annual Needs for the List I Chemicals
Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2011
AGENCY: Drug Enforcement Administration (DEA), Justice.
ACTION: Notice of Assessment of Annual Needs for 2011.
-----------------------------------------------------------------------
SUMMARY: This notice establishes the initial 2011 Assessment of Annual
Needs for certain List I chemicals in accordance with the Combat
Methamphetamine Epidemic Act of 2005 (CMEA).
DATES: Effective Date: December 20, 2010.
FOR FURTHER INFORMATION CONTACT: Christine A. Sannerud, PhD, Chief,
Drug and Chemical Evaluation Section, Drug Enforcement Administration,
8701 Morrissette Drive, Springfield, Virginia 22152, Telephone: (202)
307-7183.
SUPPLEMENTARY INFORMATION: Section 713 of the Combat Methamphetamine
Epidemic Act of 2005 (Title VII of Pub. L. 109-177) (CMEA) amended
Section 306 of the Controlled Substances Act (CSA) (21 U.S.C. 826) by
adding ephedrine, pseudoephedrine, and phenylpropanolamine to existing
language to read as follows: ``The Attorney General shall determine the
total quantity and establish production quotas for each basic class of
controlled substance in schedules I and II and for ephedrine,
pseudoephedrine, and phenylpropanolamine to be manufactured each
calendar year to provide for the estimated medical, scientific,
research, and industrial needs of the United States, for lawful export
requirements, and for the establishment and maintenance of reserve
stocks.'' Further, section 715 of the CMEA amended 21 U.S.C. 952
``Importation of Controlled Substances'' by adding the same List I
chemicals to the existing language in paragraph (a), and by adding a
new paragraph (d) to read as follows:
(a) Controlled substances in schedule I or II and narcotic drugs
in schedule III, IV, or V; exceptions
It shall be unlawful to import into the customs territory of the
United States from any place outside thereof (but within the United
States), or to import into the United States from any place outside
thereof, any controlled substance in schedule I or II of subchapter
I of this chapter, or any narcotic drug in schedule III, IV, or V of
subchapter I of this chapter, or ephedrine, pseudoephedrine, and
phenylpropanolamine, except that--
(1) such amounts of crude opium, poppy straw, concentrate of
poppy straw, and coca leaves, and of ephedrine, pseudoephedrine, and
phenylpropanolamine, as the Attorney General finds to be necessary
to provide for medical, scientific, or other legitimate purposes * *
* may be so imported under such regulations as the Attorney General
shall prescribe.
* * * * *
(d)(1) With respect to a registrant under section 958 who is
authorized under subsection (a)(1) to import ephedrine,
pseudoephedrine, or phenylpropanolamine, at any time during the year
the registrant may apply for an increase in the amount of such
chemical that the registrant is authorized to import, and the
Attorney General may
[[Page 79408]]
approve the application if the Attorney General determines that the
approval is necessary to provide for medical, scientific, or other
legitimate purposes regarding the chemical.
Editor's Note: This excerpt of the amendment is published for
the convenience of the reader. The official text is published at 21
U.S.C. 952(a) and (d)(1).
Background and Legal Authority
Section 713 of the CMEA of 2005 (Title VII of Pub. L. 109-177)
amended section 306 of the CSA (21 U.S.C. 826) to require that the
Attorney General establish quotas to provide for the annual needs for
ephedrine, pseudoephedrine, and phenylpropanolamine. Section 715 of the
CMEA amended 21 U.S.C. 952 by adding ephedrine, pseudoephedrine, and
phenylpropanolamine to the existing language concerning importation of
controlled substances.
The 2011 Assessment of Annual Needs represents those quantities of
ephedrine, pseudoephedrine, and phenylpropanolamine which may be
manufactured domestically and/or imported into the United States in
2011 to provide adequate supplies of each chemical for: the estimated
medical, scientific, research, and industrial needs of the United
States; lawful export requirements; and the establishment and
maintenance of reserve stocks.
The responsibility for establishing the assessment has been
delegated to the Administrator of the DEA by 28 CFR 0.100. The
Administrator, in turn, has redelegated this function to the Deputy
Administrator, pursuant to 28 CFR 0.104.
On September 13, 2010, a notice entitled, ``Assessment of Annual
Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and
Phenylpropanolamine for 2011: Proposed'' was published in the Federal
Register (75 FR 55605). That notice proposed the 2011 Assessment of
Annual Needs for ephedrine (for sale), ephedrine (for conversion),
pseudoephedrine (for sale), phenylpropanolamine (for sale) and
phenylpropanolamine (for conversion). All interested persons were
invited to comment on or object to the assessments on or before October
13, 2010.
Comments Received
DEA received one comment regarding the assessment for annual needs
for phenylpropanolamine (for conversion). DEA discusses this comment in
further detail below. DEA did not receive any comments to the
Assessment of Annual Needs for ephedrine (for sale), ephedrine (for
conversion), pseudoephedrine (for sale), and phenylpropanolamine (for
sale). DEA is finalizing the assessments for these List I chemicals
based on information contained in applications for 2011 import,
manufacturing and procurement quotas provided by DEA registered
importers and manufacturers as of October 21, 2010. DEA is providing
the data used in developing the established assessments for each of the
listed chemicals. DEA also notes that the Assessment of Annual Needs
may be adjusted at a later date pursuant to 21 CFR 1315.13.
Comment Regarding DEA's Assessment for Phenylpropanolamine (For
Conversion)
DEA received one comment regarding the assessment of annual need
for phenylpropanolamine (for conversion). The comment was from a DEA
registered manufacturer of phenylpropanolamine (for conversion) who
converts phenylpropanolamine to amphetamine. The commenter stated that,
``the proposed quantities for the material mentioned below is not
sufficient to provide for adequate supplies for the medical,
scientific, research and industrial needs of the United States, and for
the lawful export requirements, and that the quotas should be increased
to cover our needs * * *.'' Additionally, the commenter further stated,
``the Phenylpropanolamine quota should be increased by 8,500,000 grams
as base to allow for increased quantity of material to be purchased
from our importer of record * * *.''
DEA Response
As a preliminary matter, this Federal Register notice establishes
the assessment of annual needs for List I chemicals and the methodology
used by the DEA to set that number. The assessment of annual needs is
different than individual quotas and this rulemaking does not address
the regulatory process for evaluating individual import, manufacturing
and procurement quotas issued to DEA registered manufacturers and
importers.
In calculating the assessment for phenylpropanolamine (for
conversion) DEA considered the commenter's phenylpropanolamine
requirements, as submitted in the commenter's request for quota, along
with the requirements of other manufacturers of phenylpropanolamine as
stated in requests for 2011 quotas for the manufacture of
phenylpropanolamine (for conversion) received as of October 21, 2010.
The commenter suggested that the phenylpropanolamine assessment be
increased by 8,500 kg. DEA notes that based on the sales information
provided in pending 2011 requests for individual manufacturing quotas,
the DEA is establishing the phenylpropanolamine (for conversion) at
21,800 kg, which represents an increase of 13,700 kg from the original
8,100 kg proposed phenylpropanolamine assessment (75 FR 55609). The
full calculation is provided below.
Underlying Data and DEA's Analysis
DEA is establishing the assessment of annual needs based on
information provided by DEA registered manufacturers and importers as
of October 21, 2010. A summary of the underlying data from quota
applications and other sources, as well as DEA's analysis of that data,
are provided below.
In determining the proposed 2011 assessments, DEA has considered
the total net disposals (i.e. sales) of the List I chemicals for the
current and preceding two years, actual and estimated inventories,
projected demand (2011), industrial use, and export requirements from
data provided by DEA registered manufacturers and importers in
procurement quota applications (DEA 250), from manufacturing quota
applications (DEA 189), and from import quota applications (DEA
488).\1\
---------------------------------------------------------------------------
\1\ Applications and instructions for procurement, import and
manufacturing quotas can be found at http://www.deadiversion.usdoj.gov/quotas/quota_apps.htm.
---------------------------------------------------------------------------
DEA further considered trends as derived from information provided
in applications for import, manufacturing, and procurement quotas and
in import and in export declarations. DEA notes that the inventory,
acquisitions (purchases) and disposition (sales) data provided by DEA
registered manufacturers and importers reflects the most current
information available.
Ephedrine (for Sale) Data
[[Page 79409]]
Ephedrine (for Sale) Data for 2011 Assessment of Annual Needs
(Kilograms)
------------------------------------------------------------------------
2011
Ephedrine 2008 2009 2010 Request
------------------------------------------------------------------------
Sales* (DEA 250)............ 2,640 2,302 3,014 3,685
Imports** (DEA 488)......... 1,692 4,208 3,202 3,302
Export Declarations (DEA 18 64 52 n/a
486).......................
Inventory* (DEA 250)........ 603 432 457 n/a
IMS*** (NSP)................ 1,460 1,406 n/a n/a
------------------------------------------------------------------------
* Reported sales and inventory from applications for 2011 procurement
quotas (DEA 250) received as of October 21, 2010.
** Reported imports from applications for 2011 import quotas (DEA 488)
received as of October 21, 2010.
*** IMS Health, IMS National Sales Perspectives \TM\, January 2008 to
December 2009, Retail and Non-Retail Channels, Data Extracted October
21, 2010.
Ephedrine (for Sale) Analysis
DEA calculated the proposed 2011 Assessment of Annual Needs for
ephedrine using the calculation developed to determine the 2009
Assessment of Annual Needs. This calculation considers the criteria
defined in 21 U.S.C. 826: Estimated medical, scientific, research, and
industrial needs of the United States; lawful export requirements; and
the establishment and maintenance of reserve stocks.
As of October 21, 2010, DEA registered manufacturers of dosage form
products containing ephedrine requested the authority to purchase a
total of 3,685 kg ephedrine (for sale) in 2011. DEA registered
manufacturers of ephedrine reported sales totaling approximately 2,302
kg in 2009 and 3,014 kg in 2010; this represents a 24 percent increase
in sales reported by these firms from 2009 to 2010. Additionally,
exports of ephedrine products from the United States as reported on
export declarations (DEA 486) totaled 64 kg in 2009 and 52 kg in 2010;
this represents a 19 percent decrease from levels observed in 2009. The
average of the 2009 and 2010 exports of ephedrine products is
approximately 58 kg. DEA also considered information on trends in the
national rate of net disposals from sales data provided by IMS Health's
NSP database. IMS NSP data reported the average sales volume of
ephedrine for the calendar years 2008 and 2009 to be approximately
1,433 kg. DEA notes that the 2010 sales figure reported by
manufacturers (3,014 kg) is higher than the average sales reported by
IMS for the previous two years (1,433 kg). This is expected because a
manufacturer's reported sales include quantities which are necessary to
provide reserve stocks for distributors and retailers. In considering
the manufacturer's reported sales, DEA thus believes that 3,014 kg
fairly represents the U.S. sales of ephedrine for 2011 and that 58 kg
fairly represents the export requirements of ephedrine. For the
establishment and maintenance of reserve stocks, DEA notes that 21 CFR
Sec. 1315.24 allows for an inventory allowance (reserve stock) of 50
percent of a manufacturer's estimated sales. DEA also considered the
estimated 2010 year end inventory as reported by DEA registrants in
determining the inventory allowance.
DEA calculated the ephedrine (for sale) assessment by the following
methodology:
2010 sales + reserve stock + export requirement - existing inventory =
AAN
3,014 + (50%* 3,014) + 58 - 457 = 4,122 kg ephedrine (for sale) for
2011
This calculation suggests that DEA's Assessment of Annual Needs for
ephedrine should be established as 4,200 kg. Accordingly, DEA is
establishing the 2011 Assessment of Annual Needs for ephedrine (for
sale) at 4,200 kg.
Phenylpropanolamine (for Sale) Data
Phenylpropanolamine (for Sale) Data for 2011 Assessment of Annual Needs
(Kilograms)
------------------------------------------------------------------------
Phenylpropanolamine (for 2011
sale) 2008 2009 2010 Request
------------------------------------------------------------------------
Sales* (DEA 250)............ 4,300 4,825 5,005 6,110
Imports** (DEA 488)......... 105 1,503 1,582 1,596
Export Declarations (DEA 0 3 0 n/a
486).......................
Inventory* (DEA 250)........ 2,455 2,483 2,261 n/a
------------------------------------------------------------------------
* Reported sales and inventory from applications for 2011 procurement
quotas (DEA 250) received as of October 21, 2010.
** Reported imports from applications for 2011 import quotas (DEA 488)
received as of October 21, 2010.
Phenylpropanolamine (for Sale) Analysis
DEA utilized the same general methodology and calculation to
establish the assessment for phenylpropanolamine (for sale) as was
described for the assessment of ephedrine (for sale), above.
As of October 21, 2010, DEA registered manufacturers of dosage form
products containing phenylpropanolamine requested the authority to
purchase 6,110 kg phenylpropanolamine (for sale) in 2011. DEA
registered manufacturers of phenylpropanolamine reported sales totaling
approximately 4,825 kg in 2009 and 5,005 kg in 2010; this represents a
3.6 percent increase in sales reported by these firms from 2009 to
2010. Additionally, exports of phenylpropanolamine products from the
U.S. as reported on export declarations (DEA 486) totaled 3 kg in 2009
and 0 kg in 2010; this represents a 3 kg decrease from levels observed
in 2009. The average of the 2009 and 2010 exports of
phenylpropanolamine products is approximately 2 kg. DEA thus believes
that 5,005 kg fairly represents the U.S. sales of phenylpropanolamine
for 2011 and that 2 kg fairly represents the export requirements of
phenylpropanolamine. DEA notes that phenylpropanolamine is sold
primarily as a veterinary product for the treatment for canine
incontinence and is not approved for human consumption. IMS Health's
NSP
[[Page 79410]]
Data does not capture sales of phenylpropanolamine to these channels
and is therefore not included.
DEA calculated the phenylpropanolamine (for sale) assessment by the
following methodology:
2010 sales + reserve stock + export requirement - existing inventory =
AAN
5,005 + (50% * 5,005) + 2 - 2,261 = 5,249 kg phenylpropanolamine (for
sale) for 2011
This calculation suggests that DEA's 2011 Assessment of Annual
Needs for phenylpropanolamine (for sale) should be established as 5,300
kg. Accordingly, DEA is establishing the 2011 Assessment of Annual
Needs for phenylpropanolamine (for sale) at 5,300 kg.
Pseudoephedrine (for Sale) Data
Pseudoephedrine (for Sale) Data for 2011 Assessment of Annual Needs (Kilograms)
----------------------------------------------------------------------------------------------------------------
2011
Pseudoephedrine (for sale) 2008 2009 2010 Request
----------------------------------------------------------------------------------------------------------------
Sales* (DEA 250)............................................ 200,235 193,092 203,734 218,037.
Sales* (DEA 189)............................................ 64,781 7,321 5,550 0.
Imports** (DEA 488)......................................... 138,602 164,906 168,618 220,926.
Export Declarations (DEA 486)............................... 47,199 35,264 8,480 n/a.
Inventory* (DEA 250)........................................ 109,427 76,505 48,004 n/a.
IMS*** (NSP)................................................ 148,456 139,908 n/a n/a.
----------------------------------------------------------------------------------------------------------------
* Reported sales and inventory from applications for 2011 procurement quotas (DEA 250) received as of October
21, 2010.
** Reported imports from applications for 2011 import quotas (DEA 488) received as of October 21, 2010.
*** IMS Health, IMS National Sales Perspectives \TM\, January 2008 to December 2009, Retail and Non-Retail
Channels, Data Extracted October 21, 2010.
Pseudoephedrine (for Sale) Analysis
DEA utilized the same general methodology and calculations to
establish the assessment for pseudoephedrine (for sale) as were
described for the assessment of ephedrine (for sale), above.
As of October 21, 2010, DEA registered manufacturers of dosage form
products containing pseudoephedrine requested the authority to purchase
218,037 kg pseudoephedrine. DEA registered manufacturers of
pseudoephedrine reported sales totaling approximately 193,092 kg in
2009 and 203,734 kg in 2010; this represents a 5 percent increase in
sales reported by these firms from 2009 to 2010. During the same period
exports of pseudoephedrine products from the U.S. as reported on export
declarations (DEA 486) totaled 35,264 kg in 2009 and 8,480 kg in 2010;
this represents a 76 percent decrease from levels observed in 2009. The
average of the 2009 and 2010 exports is 21,872 kg.
Additionally, DEA considered information on trends in the national
rate of net disposals from sales data provided by IMS Health. IMS NSP
data reported the average retail sales volume of pseudoephedrine for
the calendar years 2008 and 2009 to be approximately 144,182 kg. DEA
thus believes that 203,734 kg of sales reported by manufacturers fairly
represents the U.S. sales of pseudoephedrine for 2011 and that 21,872
kg fairly represents the export requirements for pseudoephedrine.
DEA calculated the pseudoephedrine (for sale) assessment by the
following methodology:
2010 sales + reserve stock + export requirement - existing inventory =
AAN
203,734 + (50% * 203,734) + 21,872 - 48,004 = 279,469 kg
pseudoephedrine (for sale) for 2011.
This calculation suggests that DEA's 2011 Assessment of Annual
Needs for pseudoephedrine (for sale) should be established as 280,000
kg. Accordingly, DEA is establishing the 2011 Assessment of Annual
Needs for pseudoephedrine (for sale) at 280,000 kg.
Phenylpropanolamine (for Conversion) Data
Phenylpropanolamine (for Conversion) Data for 2011 Assessment of Annual
Needs (Kilograms)
------------------------------------------------------------------------
Phenylpropanolamine (for 2011
conversion) 2008 2009 2010 Request
------------------------------------------------------------------------
Sales* (DEA 250)............ 10,834 11,486 17,086 23,700
Imports** (DEA 488)......... 8,294 5,766 15,177 27,500
Export Declarations (DEA 0 0 0 n/a
486).......................
Inventory* (DEA 250)........ 5,533 3,145 3,854 n/a
------------------------------------------------------------------------
* Reported sales and inventory from applications for 2011 procurement
quotas (DEA 250) received as of received as of October 21, 2010.
** Reported imports from applications for 2011 import quotas (DEA 488)
received as of October 21, 2010.
Phenylpropanolamine (for Conversion) Analysis
As of October 21, 2010, DEA registered manufacturers of
phenylpropanolamine (for conversion) requested the authority to
purchase a total of 23,700 kg phenylpropanolamine for the manufacture
of amphetamine. DEA registered manufacturers of phenylpropanolamine
reported sales of phenylpropanolamine totaling approximately 11,486 kg
in 2009 and 17,086 kg in 2010; this represents a 33 percent increase in
sales reported by these firms from 2009 to 2010. There were no reported
exports of phenylpropanolamine (for conversion). DEA has not received
any requests to synthesize phenylpropanolamine in 2011. DEA has
concluded that the 2010 sales of phenylpropanolamine (for conversion),
17,086 kg, fairly represents U.S. requirements for 2011 and zero kg
fairly represents the export requirements of phenylpropanolamine (for
conversion).
DEA determined that the data provided in procurement,
manufacturing, and import quota applications best represents the
legitimate need for phenylpropanolamine (for conversion).
[[Page 79411]]
Phenylpropanolamine (for conversion) is used for the manufacture of
legitimate amphetamine products, but DEA notes that most legitimate
amphetamine is manufactured by converting phenylacetone, rather than
phenylpropanolamine, to amphetamine. Basing the phenylpropanolamine
(for conversion) calculation on the total Aggregate Production Quota
(APQ) for amphetamine therefore would inaccurately inflate the
phenylpropanolamine (for conversion) assessment.
DEA calculated the phenylpropanolamine (for conversion) assessment
for the manufacture of amphetamine as follows:
(2010 sales) + reserve stock + export requirement - inventory = AAN
(17,086) + (50%*17,086) + 0 - 3,854 = 21,775 kg PPA (for conversion)
for 2011
This calculation suggests that DEA's 2011 Assessment of Annual
Needs for phenylpropanolamine (for conversion) should be established as
21,800 kg. Accordingly, DEA is establishing the 2011 Assessment of
Annual Needs for phenylpropanolamine (for conversion) at 21,800 kg.
Ephedrine (for Conversion) Data
Ephedrine (for Conversion) Data for 2011 Assessment of Annual Needs
(Kilograms)
------------------------------------------------------------------------
2011
Ephedrine (for conversion) 2008 2009 2010 Request
------------------------------------------------------------------------
Sales* (DEA 250)............ 64,665 9,562 6,303 653
Imports** (DEA 488)......... 0 0 0 0
Inventory* (DEA 250)........ 233 99 152 n/a
APQ Methamphetamine***...... 3,130 3,130 3,130 n/a
------------------------------------------------------------------------
* Reported sales and inventory from applications for 2011 procurement
quotas (DEA 250) and manufacturing quotas (DEA 189) received as of
received as of October 21, 2010.
** Reported imports from applications for 2011 import quotas (DEA 488)
received as of received as of October 21, 2010.
*** Methamphetamine Aggregate Production Quota History http://www.deadiversion.usdoj.gov/quotas/quota_history.pdf.
Ephedrine (for Conversion) Analysis
As of October 21, 2010, DEA registered manufacturers of ephedrine
(for conversion) requested the authority to purchase a total of 653 kg
ephedrine (for conversion) for the manufacture of two substances:
methamphetamine and pseudoephedrine.
DEA considered the ephedrine (for conversion) requirements for the
manufacture of methamphetamine and pseudoephedrine. DEA has determined
that the established assessments for the manufacture of these two
substances are the best indicators of the need for ephedrine (for
conversion). The assessment of need for methamphetamine was determined
by DEA as the Aggregate Production Quota (APQ) for methamphetamine. DEA
determined that the estimated sales of pseudoephedrine, as referenced
in the Assessment of Annual Needs (AAN) for pseudoephedrine, represents
the need for pseudoephedrine. Reported sales of ephedrine (for
conversion) are included as reference to DEA's methodology.
DEA further considered the reported conversion yields of these
substances. DEA registered manufacturers reported a conversion yield of
39 percent for the synthesis of methamphetamine from ephedrine. DEA
cannot disclose the conversion yield for the synthesis of
pseudoephedrine because this information is proprietary to the one
manufacturer involved in this type of manufacturing.
DEA calculated the ephedrine (for conversion) assessment by the
following methodology:
methamphetamine requirement + pseudoephedrine requirement = AAN
DEA calculated the ephedrine (for conversion) requirement for the
manufacture of methamphetamine as follows:
(2010 APQ methamphetamine/39 percent yield) + reserve stock - inventory
= ephedrine (for manufacture of methamphetamine)
(3,130/39 percent yield) + 50 percent*(3,130/39 percent yield) - 152 =
11,887 kg
The calculation for the ephedrine (for conversion) requirement for
the manufacture of pseudoephedrine leads to a result of 6,692 kg. DEA
cannot provide the details of the calculation because this would reveal
the conversion yield for the synthesis of pseudoephedrine, which is
proprietary to the one manufacturer involved in this type of
manufacturing. Therefore, the assessment for ephedrine was determined
by the sum total of the ephedrine (for conversion) requirements as
described by the following methodology:
methamphetamine requirement + pseudoephedrine requirement = AAN
11,887 + 6,692 = 18,579 kg ephedrine (for conversion) for 2011
This calculation suggests that DEA's 2011 Assessment of Annual
Needs for ephedrine (for conversion) should be established as 18,600
kg. Accordingly, DEA is establishing the 2011 Assessment of Annual
Needs for ephedrine (for conversion) at 18,600 kg.
Conclusion
DEA received one comment regarding the assessment for
phenylpropanolamine (for conversion). DEA has carefully considered the
comment received in connection with the 2011 Assessment of Annual
Needs. DEA calculated the assessment for phenylpropanolamine (for
conversion) using the data provided in applications for 2011 import,
manufacturing and procurement quotas provided by DEA registered
importers and manufacturers as of October 21, 2010. This data included
the quota request submitted by the commenter. The results of the
calculation led DEA to increase the phenylpropanolamine (for
conversion) assessment from the proposed 8,100 kg to 21,800 kg.
DEA did not receive any comments on its Assessment of Annual Needs
for ephedrine (for sale), ephedrine (for conversion), pseudoephedrine
(for sale) and phenylpropanolamine (for sale). DEA is finalizing the
assessments for these List I chemicals based on information contained
in applications for 2011 import, manufacturing and procurement quotas
provided by DEA registered importers and manufacturers as of October
21, 2010.
Therefore, under the authority vested in the Attorney General by
Section 306 of the CSA (21 U.S.C. 826), and delegated to the
Administrator of the DEA by 28 CFR 0.100, and redelegated to the Deputy
Administrator pursuant to 28 CFR 0.104, the Deputy Administrator hereby
orders that the 2011 Assessment of Annual Needs for ephedrine,
[[Page 79412]]
pseudoephedrine, and phenylpropanolamine, expressed in kilograms of
anhydrous acid or base, be established as follows:
------------------------------------------------------------------------
Established
2011
List I chemical assessment of
annual needs
(kg)
------------------------------------------------------------------------
Ephedrine (for sale).................................... 4,200
Phenylpropanolamine (for sale).......................... 5,300
Pseudoephedrine (for sale).............................. 280,000
Phenylpropanolamine (for conversion).................... 21,800
Ephedrine (for conversion).............................. 18,600
------------------------------------------------------------------------
The Office of Management and Budget has determined that notices of
quotas are not subject to centralized review under Executive Order
12866.
This action does not preempt or modify any provision of State law;
nor does it impose enforcement responsibilities on any State; nor does
it diminish the power of any State to enforce its own laws.
Accordingly, this action does not have any federalism implications
warranting the application of Executive Order 13132.
The Deputy Administrator hereby certifies that this action will not
have a significant economic impact upon a substantial number of small
entities whose interests must be considered under the Regulatory
Flexibility Act, 5 U.S.C. 601-612. The establishment of Assessment of
Annual Needs for ephedrine, pseudoephedrine, and phenylpropanolamine is
mandated by law. The assessments are necessary to provide for the
estimated medical, scientific, research and industrial needs of the
United States; for lawful export requirements; and the establishment
and maintenance of reserve stocks. Accordingly, the Deputy
Administrator has determined that this action does not require a
regulatory flexibility analysis.
This action meets the applicable standards set forth in Sections
3(a) and 3(b)(2) of Executive Order 12988 Civil Justice Reform.
This action will not result in the expenditure by State, local, and
Tribal governments, in the aggregate, or by the private sector, of
$120,000,000 or more (adjusted for inflation) in any one year, and will
not significantly or uniquely affect small governments. Therefore, no
actions were deemed necessary under the provisions of the Unfunded
Mandates Reform Act of 1995.
This action is not a major rule as defined by Section 804 of the
Small Business Regulatory Enforcement Fairness Act of 1996
(Congressional Review Act). This action will not result in an annual
effect on the economy of $100,000,000 or more; a major increase in
costs or prices; or significant adverse effects on competition,
employment, investment, productivity, innovation, or on the ability of
United States-based companies to compete with foreign-based companies
in domestic and export markets.
Dated: December 10, 2010.
Michele M. Leonhart,
Deputy Administrator.
[FR Doc. 2010-31853 Filed 12-17-10; 8:45 am]
BILLING CODE 4410-09-P